Standard International prognostic index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era.

J Clin Oncol 2010 May 12;28(14):2373-80. Epub 2010 Apr 12.

Dipl-Math, Institute for Medical Informatics, Statistics, and Epidemiology, Universität Leipzig, Härtelstrasse 16-18, D-04107 Leipzig, Germany.

Purpose: The International Prognostic Index (IPI) is widely used for risk stratification of patients with aggressive B-cell lymphoma. The introduction of rituximab has markedly improved outcome, and R-CHOP (rituximab + cyclophosphamide, doxorubicin, vincristine, prednisone) has become the standard treatment for CD20(+) diffuse large B-cell lymphoma. To investigate whether the IPI has maintained its power for risk stratification when rituximab is combined with CHOP, we analyzed the prognostic relevance of IPI in three prospective clinical trials.

Patients And Methods: In total, 1,062 patients treated with rituximab were included (MabThera International Trial [MInT], 380 patients; dose-escalated regimen of cyclophosphamide, doxorubicin, vincristine, etoposide, and prednisone (MegaCHOEP) trial, 72 patients; CHOP + rituximab for patients older than age 60 years [RICOVER-60] trial, 610 patients). A multivariate proportional hazards modeling was performed for single IPI factors under rituximab on event-free, progression-free, and overall survival.

Results: IPI score was significant for all three end points. Rituximab significantly improved treatment outcome within each IPI group resulting in a quenching of the Kaplan-Meier estimators. However, IPI was a significant prognostic factor in all three end points and the ordering of the IPI groups remained valid. The relative risk estimates of single IPI factors and their order in patients treated with R-CHOP were similar to those found with CHOP.

Conclusion: The effects of rituximab were superimposed on the effects of CHOP with no interactions between chemotherapy and antibody therapy. These results demonstrate that the IPI is still valid in the R-CHOP era.

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2009.26.2493DOI Listing
May 2010
54 Reads

Publication Analysis

Top Keywords

b-cell lymphoma
12
ipi
10
rituximab
9
patients aggressive
8
single ipi
8
patients
8
ipi factors
8
doxorubicin vincristine
8
cyclophosphamide doxorubicin
8
international prognostic
8
patients treated
8
three points
8
risk stratification
8
[ricover-60] trial
4
years [ricover-60]
4
patients multivariate
4
trial 610
4
610 patients
4
performed single
4
rituximab event-free
4

Altmetric Statistics

Similar Publications